Findings on Atrial Fibrillation Detailed by Investigators at University of Copenhagen (Oncotherapeutic Protein Kinase Inhibitors Associated With Pro-arrhythmic Liability)

摘要

2021 MAY 05 (NewsRx) - By a News Reporter-Staff News Editor at Disease Prevention Daily-Investigators publish new report on Heart Disorders and Diseases - Atrial Fibrillation. According to news originating from Copenhagen, Denmark, by NewsRx correspondents, research stated, "Ibrutinib is a protein kinase inhibitor that has been widely successful in treating multiple common variations of B-cell cancers. However, an unfortunate side effect of ibrutinib is that it predisposes patients to development of atrial fibrillation." Financial support for this research came from Novo Nordisk Foundation. Our news journalists obtained a quote from the research from the University of Copenhagen, "The purpose of this study was to assess other commonly prescribed protein kinase inhibitors for similar pro-arrhythmic liability. This study comprehensively evaluated data from the U.S. Food and Drug Administration adverse events reporting system and determined the reporting of cardiac arrhythmia attributed to kinase inhibitor therapy using a multivariable logistic regression model.